Volume 11, Number 8—August 2005
Dispatch
Cost-Benefit of Stockpiling Drugs for Influenza Pandemic
Table A2
Cost and benefit parameters included in the model
Variable | Point estimate (US$) | Reference |
---|---|---|
Average daily wage* | 71.6 | 14 |
Cost of hospital day* | 317.8 | 14 |
Cost of physician visit*† | 45.3 | 17 |
Antiviral (NAI) drug costs‡ | ||
5-day therapeutic course | 8.9 | Roche, pers. comm. |
7-day prophylactic course | 6.2 | Roche, pers. comm |
*Converted from original prices in NIS (new Israeli shekels) at the rate of US$1 = 4.50 NIS.
†Physician costs include prescription drugs and diagnostic tests.
‡NAI, neuraminidase inhibitors. Based on manufacturer's quoted price for oseltamivir.
References
- WHO consultation on priority public health interventions before and during an influenza pandemic, Geneva, 16–18 March 2004. Wkly Epidemiol Rec. 2004;79:107–8.PubMedGoogle Scholar
- Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659–71. DOIPubMedGoogle Scholar
- World is ill-prepared for "inevitable" flu pandemic. Bull World Health Organ. 2004;82:317–8.PubMedGoogle Scholar
- Cohen Y. Tamiflu pharmaco-economic dossier, part C: evaluation of influenza cost of illness in Israel. Natanya (Israel): Quintiles Israel; 2000. p. 1–46.
- Statistical abstract of Israel 2003, no. 54. Jerusalem: Israel Central Bureau of Statistics; 2003.
- Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33. DOIPubMedGoogle Scholar
- McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs. 2001;61:263–83. DOIPubMedGoogle Scholar
- Lazzari S, Stohr K. Avian influenza and influenza pandemics. Bull World Health Organ. 2004;82:242.PubMedGoogle Scholar
- Balicer RD, Huerta M, Grotto I. Tackling the next influenza pandemic. BMJ. 2004;328:1391–2. DOIPubMedGoogle Scholar
- Blendon RJ, Benson JM, DesRoches CM, Raleigh E, Taylor-Clark K. The public's response to severe acute respiratory syndrome in Toronto and the United States. Clin Infect Dis. 2004;38:925–31. DOIPubMedGoogle Scholar
- Finland says it's to buy stocks of Roche's Tamiflu. Reuters Health Information [serial online], Mar 10, 2005 [cited 15 May 2005]. Available from http://www.influenza.com/
- Coombes R. UK stocks up on antiviral drug to tackle flu outbreak. BMJ. 2005;330:495. DOIPubMedGoogle Scholar
- Statistical abstract of Israel 2003, no. 54. Jerusalem: Israel Central Bureau of Statistics; 2003.
- Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis. 1999;5:659–71. DOIPubMedGoogle Scholar
- Cohen Y. Tamiflu pharmaco-economic dossier, part C: evaluation of influenza cost of illness in Israel. Netanya (Israel): Quintiles Israel; 2000. p. 1–46.
- Saito R, Oshitani H, Masuda H, Suzuki H. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol. 2002;40:84–8. DOIPubMedGoogle Scholar
- Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med. 1989;321:1696–702. DOIPubMedGoogle Scholar
- World Health Organization Department of Communicable Disease Surveillance and Response. Avian influenza A(H5N1)—update 22: first data on patients from Viet Nam, clinical data from Hong Kong 1997, susceptibility of H5N1 viruses to antiviral drugs. 2004 Feb 12 [cited 2005 May 25]. Available from http://www.who.int/csr/don/2004_02_12a/en/
- Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000;48:101–15. DOIPubMedGoogle Scholar
- Israeli Ministry of Health. Oseltamivir phosphate. The Israel Drug Registry. 2005 May 24 [cited 2005 May 25]. Available from http://www.health.gov.il/units/pharmacy/trufot/PerutTrufa.asp? Reg_Number=118%2079%2029952%2000&safa=e
- Kirkbride H, Watson J. A review of the use of neuraminidase inhibitors for prophylaxis of influenza. NI paper for communicable disease and public health (CDPH). UK Health Protection Agency. 2002 Sep 27 [cited 2005 May 25]. Available from http://www.hpa.org.uk/infections/publications/pdf/Neuramindase.pdf
- Centers for Disease Control and Prevention. Antiviral agents for influenza: background information for clinicians. 2003 Dec 16 [cited 2005 May 25]. Available from http://www.cdc.gov/flu/professionals/pdf/antiviralsbackground.pdf
- Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336–43. DOIPubMedGoogle Scholar
- Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016–24. DOIPubMedGoogle Scholar
- Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235–41. DOIPubMedGoogle Scholar
- Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–72. DOIPubMedGoogle Scholar
- Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282:31–5. DOIPubMedGoogle Scholar
- Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159:623–33. DOIPubMedGoogle Scholar
- Oxford JS, Bossuyt S, Balasingam S, Mann A, Novelli P, Lambkin R. Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin Microbiol Infect. 2003;9:1–14. DOIPubMedGoogle Scholar
- Breslow NE. Elementary methods of cohort analysis. Int J Epidemiol. 1984;13:112–5. DOIPubMedGoogle Scholar
- Fleiss JL. The measurement of interrater agreement. In Fleiss JL, editor. Statistical methods for rates and proportions. New York: Wiley; 1981. p. 212–36.
- Kleinbaum DG, Kupper LL, Morganstern H. Stratified analysis. In: Epidemiologic research. New York: Van Nostrand Reinhold; 1982. p. 321–76.
- Abramson JH, Gahlinger PM. Computer programs for epidemiologists: PEPI Version 4.0. Salt Lake City (UT): Sagebrush Press; 2001.
- Balicer RD, Huerta M, Grotto I. Tackling the next influenza pandemic. BMJ. 2004;328:1391–2. DOIPubMedGoogle Scholar
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.